logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Osteoporosis Postmenopausal

    FiltersReset Filters
    27 results

    • alendronate

      (Alendronate sodium tablet)
      Marlex Pharmaceuticals Inc
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, preventing postmenopausal osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone in symptomatic patients or those at risk for complications. Reinforcement of therapy need is recommended periodically.

    • atelvia

      (risedronate sodium)
      Allergan, Inc.
      Usage: Atelvia is indicated for the treatment of osteoporosis in postmenopausal women, demonstrating effectiveness in reducing vertebral and nonvertebral osteoporosis-related fractures. The optimal duration of use is unspecified, with periodic reassessment needed for continued therapy, especially in low-risk patients.

    • calcitonin salmon

      (CALCITONIN SALMON)
      Cipla USA Inc.
      Usage: Calcitonin salmon injection is indicated for treating symptomatic Paget's disease of bone, hypercalcemic emergencies, and postmenopausal osteoporosis in women over five years postmenopause. It is recommended for patients unable to use alternative treatments, and the need for continued therapy should be periodically reassessed due to potential malignancy risk.

    • climara

      (Estradiol)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: This drug is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, hypoestrogenism from hypogonadism or primary ovarian failure, and for the prevention of postmenopausal osteoporosis, with specific limitations on its use for atrophy and osteoporosis.

    • climara pro

      (Estradiol and Levonorgestrel)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: Climara Pro is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis, specifically in women at significant risk. Non-estrogen medications should be considered first for osteoporosis prevention.

    • duavee

      (conjugated estrogens/bazedoxifene)
      Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
      Usage: DUAVEE is indicated for women with a uterus to treat moderate to severe menopausal vasomotor symptoms and to prevent postmenopausal osteoporosis. Treatment duration should be minimal and reconsidered periodically, focusing on women at significant risk of osteoporosis.

    • estradiol transdermal system

      (Estradiol)
      Sandoz Inc
      Usage: The Estradiol Transdermal System is indicated for treating moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, hypoestrogenism from various causes, and prevention of postmenopausal osteoporosis, with specific limitations for certain conditions.

    • etyqa

      (ESTRADIOL AND NORETHINDRONE ACETATE)
      Aurobindo Pharma Limited
      Usage: Etyqa is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, as well as for the prevention of postmenopausal osteoporosis in women at significant risk. Topical products are preferred for vaginal atrophy, and non-estrogen options are recommended for osteoporosis.

    • evenity

      (romosozumab-aqqg)
      Amgen Inc
      Usage: EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high fracture risk, including those with a history of fractures or multiple risk factors, or those intolerant to other therapies. Limitation: use is restricted to 12 monthly doses due to waning effectiveness.

    • ibandronate sodium

      (Ibandronate sodium)
      Dr. Reddy's Laboratories Limited
      Usage: Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. They increase bone mineral density and reduce vertebral fracture incidence. The optimal duration of therapy is undetermined, and ongoing evaluation of the need for continued treatment is recommended.